Cue Biopharma Inc Revenue Growth Rates (CUE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cue Biopharma Inc   (NASDAQ: CUE)
 

CUE's Revenue Growth by Quarter and Year

Cue Biopharma Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CUE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 7.88
1st Quarter March 5.69
FY 13.57

CUEs Annual Revenue
Cue Biopharma Inc 's Revenue in the fiscal year 2025 $ 27.47 millions
Cue Biopharma Inc 's Revenue in the fiscal year 2024 $ 9.29 millions
Cue Biopharma Inc 's Revenue in the fiscal year 2023 $ 5.49 millions
Cue Biopharma Inc 's Revenue in the fiscal year 2022 $ 1.25 millions
Cue Biopharma Inc 's Revenue in the fiscal year 2021 $ 14.94 millions




CUE Revenue second quarter 2026 Y/Y Growth Comment
Cue Biopharma Inc reported Revenue surge of 167.02% year on year in the second quarter 2026, to $ 7.88 millions, this is lower than Cue Biopharma Inc 's recent average Revenue surge of 189.14%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue growth. While Cue Biopharma Inc ' s Revenue doubling of 167.02% ranks overall at the positon no. 2090 in the second quarter 2026.


CUE Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 1288.61 % -13.19 % 1113.33 %
3rd Quarter September - -35.63 % 59.05 % 2900 %
2nd Quarter June 167.02 % 10.9 % 92.75 % 4500 %
1st Quarter March 1254.76 % -75.58 % 805.26 % -81 %
FY   - 195.27 % 69.4 % -

Financial Statements
Cue Biopharma Inc 's second quarter 2026 Revenue $ 7.88 millions CUE's Income Statement
Cue Biopharma Inc 's second quarter 2025 Revenue $ 2.95 millions Quarterly CUE's Income Statement


CUE Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 920.47 % -52.69 % -13.33 %
3rd Quarter September - -27.12 % 25.56 % 52.17 %
2nd Quarter June 38.44 % 602.38 % 54.65 % 626.32 %
1st Quarter March -74.07 % -73.42 % -5.49 % 26.67 %
FY (Year on Year)   - 195.27 % 69.4 % -


Back to CUE Growth rate Comparisons >> Back to CUE Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #307
Overall #2090

Revenue Y/Y Growth Statistics
High Average Low
1524.15 % 189.14 % -97 %
(Mar 31 2024)   (Mar 31 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #307
Overall #2090
Revenue Y/Y Growth Statistics
High Average Low
1524.15 % 189.14 % -97 %
(Mar 31 2024)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Cue Biopharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
921.03 % 92.44 % -100 %
(Dec 31 2025)  


CUE's II. Quarter Q/Q Revenue Comment
Cue Biopharma Inc achieved in the II. Quarter 2026 below company average Revenue jump of 38.44% quarter on quarter, to $ 7.88 millions.

Within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Revenue quarter on quarter growth. While Cue Biopharma Inc 's Revenue growth quarter on quarter, overall rank is 316.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #78
Overall #316
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #78
Overall #316
Revenue Q/Q Growth Statistics
High Average Low
921.03 % 92.44 % -100 %
(Dec 31 2025)  


CUE's II. Quarter Q/Q Revenue Comment
Cue Biopharma Inc achieved in the II. Quarter 2026 below company average Revenue jump of 38.44% quarter on quarter, to $ 7.88 millions.

Within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Revenue quarter on quarter growth. While Cue Biopharma Inc 's Revenue growth quarter on quarter, overall rank is 316.


Cue Biopharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 37.65 $ 32.73 $ 27.47 $ 7.10 $ 8.29
Y / Y Revenue Growth (TTM) 354.37 % 309.6 % 195.75 % -25.51 % -0.11 %
Year on Year Revenue Growth Overall Ranking # 2472 # 963 # 119 # 46 # 27
Seqeuential Revenue Change (TTM) 15.04 % 19.17 % 286.85 % -14.32 % 3.7 %
Seq. Revenue Growth (TTM) Overall Ranking # 2090 # 2943 # 2189 # 591 # 622


Cumulative Revenue growth Comment
Cue Biopharma Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 354.37% year on year, to $ 38 millions if the fiscal year would have ended in Jun 30 2026.
Cue Biopharma Inc 's trailing twelve months Revenue growth was higher than company's average 189.14% and higher than 309.6% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 15.04 % from $32.73 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at189.14%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 15.04 % increase from $32.73 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 359 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 963 to 2472.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 360
Overall # 2472

Revenue TTM Y/Y Growth Statistics
High Average Low
1524.15 %
 189.14 %
-97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 307
S&P 500 # 2090
Cumulative Revenue growth Comment
Cue Biopharma Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 354.37% year on year, to $ 38 millions if the fiscal year would have ended in Jun 30 2026.
Cue Biopharma Inc 's trailing twelve months Revenue growth was higher than company's average 189.14% and higher than 309.6% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 15.04 % from $32.73 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at189.14%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 15.04 % increase from $32.73 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 359 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 963 to 2472.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 360
Overall # 2472

Revenue TTM Y/Y Growth Statistics
High Average Low
1524.15 %
189.14 %
-97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 307
S&P 500 # 2090




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CUE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions


About Cue Biopharma Inc Revenue Growth Rates (CUE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cue Biopharma Inc (CIK 1645460).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-352128
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cue Biopharma Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.